Under the collaboration, Vor will investigate the combination of Vor's "invisible" engineered hematopoietic stem cell transplant platform and Janssen's bispecific antibodies into a treatment solution for acute myeloid leukemia.

"We believe this unique combination will leverage each technology's strengths, while protecting patients against off-target effects of these powerful immunotherapies," said Tirtha Chakraborty, PhD, chief scientific officer of Vor.

As part of the agreement, each company will retain all rights and ownership to their respective programs and platforms. Additional financial details were not disclosed.

Vor, Abound Bio to develop multitargeted CAR T therapies
Vor Biopharma has entered into a multiyear strategic collaboration and license agreement with Abound Bio to research both single- and multitargeted chimeric...